Barclays PLC Corcept Therapeutics Inc Call Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$22.21 - $34.48 $446,421 - $693,047	20,100 Added 11.17%	200,100 $6.5 Million
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $3.8 Million - $4.94 Million	180,000 New	180,000 $4.53 Million
Q4 2021 Feb 14, 2022	BUY	$17.1 - $23.34 $28 Million - $38.2 Million	1,635,100 Added 33369.39%	1,640,000 $32.5 Million
Q4 2018 Feb 14, 2019	SELL	$11.29 - $17.19 $622,079 - $947,169	-55,100 Reduced 91.83%	4,900 $65,000
Q4 2017 Feb 14, 2018	BUY	$15.77 - $20.72 $946,200 - $1.24 Million	60,000	60,000 $1.08 Million

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.16B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.